NeuroMetrix, Inc. CEO Discusses Significance of WellMed Adoption of NC-stat® DPNCheck™

WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer cited the recent adoption of the company’s diagnostic device, NC-stat DPNCheck, by WellMed Medical Management, www.wellmedmedicalgroup.com, as important evidence of the product’s potential in the managed care sector. Dr. Gozani detailed the significance of the WellMed agreement in an interview with CEONews.Tv at: http://www.ceonews.tv/nuro/

Back to news